Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: A one-year prospective trial
Article first published online: 25 FEB 2010
© 2010 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd
Journal of Gastroenterology and Hepatology
Volume 25, Issue 9, pages 1550–1555, September 2010
How to Cite
Kuroda, H., Ushio, A., Miyamoto, Y., Sawara, K., Oikawa, K., Kasai, K., Endo, R., Takikawa, Y., Kato, A. and Suzuki, K. (2010), Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: A one-year prospective trial. Journal of Gastroenterology and Hepatology, 25: 1550–1555. doi: 10.1111/j.1440-1746.2010.06306.x
- Issue published online: 24 AUG 2010
- Article first published online: 25 FEB 2010
- Accepted for publication 8 February 2010.
- branched-chain amino acid;
- hepatocellular carcinoma;
- indirect calorimetry;
- liver cirrhosis;
- quality of life;
- radiofrequency ablation
Background and Aim: This prospective control study examined whether supplementation with branched-chain amino acid (BCAA)-enriched nutrients can help maintain and improve residual liver function and nutritional status in cirrhotic patients with hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA).
Methods: Subjects were 49 patients with hepatitis C-related HCC who underwent RFA. Two groups were formed: BCAA group (BCAA-enriched nutrient, aminoleban EN) and controls (standard diet only). Event-free survival rate, liver function tests, and Short Form (SF)-8 scores were evaluated in both groups before and one year after RFA. Energy metabolism using indirect calorimetry was measured before and after 3 months.
Results: Complete data were obtained from 35 patients (BCAA group, n = 20; controls, n = 15). Six events (death, recurrence of HCC, rupture of esophageal varices and liver failure) occurred during the observation period, but frequencies of these events did not differ between groups. Event-free survival rate tended to be higher in the BCA group than in controls. Among the parameters of liver function, serum albumin level was only significantly increased over 6 months, and remained at similar values for one year (P < 0.05). SF-8 scores for general health, physical functioning, and social functioning were significantly elevated in the BCAA group (P < 0.05). Non-protein respiratory quotient was significantly improved in the BCAA group (P < 0.01).
Conclusion: Supplementation with BCAA-enriched nutrients for one year in cirrhotic patients with HCC after RFA therapy can perform safety and improve both nutritional state and quality of life.